Navigation Links
Treatment With Prolia® (denosumab) Associated With Significantly Greater Adherence, Compliance and Persistence Compared to Alendronate
Date:3/23/2011

THOUSAND OAKS, Calif., March 23, 2011 /PRNewswire/ -- Amgen (Nasdaq: AMGN) today announced new data that showed postmenopausal women with osteoporosis had significantly greater adherence, compliance, and persistence during Prolia® (denosumab) treatment than during alendronate treatment, an oral bisphosphonate commonly used to treat osteoporosis.

Adherence to treatment, which includes both compliance (a measure of how well patients follow directions for taking medication) and persistence (a measure of whether patients continue with treatment), was measured over two years.  

Results from the DAPS (Denosumab Adherence Preference and Satisfaction) study presented at the annual European Congress on Osteoporosis and Osteoarthritis (ECCEO11-IOF) in Valencia, Spain, also found that more than 90 percent of patients preferred Prolia as a treatment option over alendronate. In addition, significantly more patients were satisfied with denosumab injection compared with alendronate tablet (mean score of 4.5 vs. 3.2; score scale of 1-5, higher score, higher satisfaction, p<0.0001).  

"Despite the availability of several treatment options, many postmenopausal women with osteoporosis are not taking their medication as prescribed and therefore remain at risk for fractures," said Professor Nick Freemantle, University of Birmingham, Birmingham, UK. "Prolia is an important treatment option for patients not only because of its efficacy and safety, but also because, as this study suggests, women may be more likely to stay on treatment compared to weekly oral alendronate."

DAPS Study ResultsDAPS was a two-year, multicenter, open-label, crossover study of 250 postmenopausal women with a bone mineral density (BMD) T-score of less than or equal to -2.0 to greater than or equal to -4.0 at the lumbar spine, total hip, or femoral neck and no prior bisphosphonate t
'/>"/>

SOURCE Amgen
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine technology :

1. Prolia® (denosumab) Open-Label Extension Trial Showed Continued Increase in Bone Mineral Density Over Five Years of Treatment With Similar Safety Profile Observed in Pivotal Trial
2. Study Demonstrates Relationship Between Subcutaneous IgG (SCIg) Dosage and Clinical Outcomes With Hizentra® Treatment in Patients With Primary Immunodeficiencies
3. AstraZeneca Initiates Phase III Clinical Programme Evaluating NKTR-118 for Treatment of Opioid-Induced Constipation
4. Optimer Pharmaceuticals Announces Issuance of Key Patent Covering Fidaxomicin Methods of Use as a Treatment of Clostridium difficile infection
5. The Balance-Based Torso-Weighting® Treatment for Multiple Sclerosis Receives a NIH Recovery Act Grant
6. Los Angeles Dentist, Dr. Kevin Sands, Uses the Latest Technologies to Provide VIP Services and Treatments for His Patients
7. International Prostate Cancer Treatment Expert Dr. David B. Samadi Supports Kenyan Minister of Medical Services, Peter Anyang Nyongos Decision to Travel to the U.S. for Prostate Cancer Treatment
8. Practice Guidelines Confirm Utility of Endoscopic Radiofrequency Ablation (RFA) for the Treatment of Barretts Esophagus
9. Pew Applauds Introduction of Preservation of Antibiotics for Medical Treatment Act of 2011
10. Tris Announces NDA Acceptance of Extended Release Carbinoxamine Oral Suspension for the Treatment of Allergies in Kids Two Years and Older
11. Genus Oncology, LLC Announces Orphan Drug Status for GO-203-2c for Treatment of Pancreatic Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... , Aug. 21, 2014  AliveCor, Inc. ... Drug Administration (FDA) has granted the company ... fibrillation (AFib), the most common form of ... instantly detects if patients are experiencing AFib ... the mobile phone based AliveCor® Heart Monitor, ...
(Date:8/21/2014)... , Aug. 21, 2014   Royal Philips ... today announced it has received 510(k) clearance from ... its precision planning application for Transcatheter Aortic-Valve Implantation ... application provides interventionalists with pre-procedural, high-precision positioning to ... TAVI planning application is available as part of ...
(Date:8/20/2014)... 20, 2014 Northstar Global Business Services, ... months of hard work from many talented specialists, ... formulation and package design.  The new formulation for ... into the product due to overwhelming evidence of ... Snorenz Nighttime will also include these vitamins, as ...
Breaking Medicine Technology:AliveCor Receives First FDA Clearance to Detect a Serious Heart Condition in an ECG on a Mobile Device 2Philips receives FDA 510(k) Clearance for TAVI Precision Treatment Planning Application 2Philips receives FDA 510(k) Clearance for TAVI Precision Treatment Planning Application 3Northstar completes the first phase of its new retail strategy and prepares to ship reformulated Snorenz with all new packaging 2
... Reported in 4Q 2007 -, LA JOLLA, ... TPTX ) today announced that it has completed,enrollment ... for the treatment,of acute migraine headache. Tezampanel is ... non-vascular and non-serotonergic,approach to the management of pain ...
... 3 trial of Genasense(R) seeks to confirm benefit in melanoma -- ... Company regains compliance for NASDAQ Global Markets listing; Genta common stock ... program for Genasense will continue ... during Phase 3 trial ...
Cached Medicine Technology:TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache 2TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache 3TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache 4Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights 2Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights 3Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights 4Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights 5Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights 6Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights 7Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights 8
(Date:8/21/2014)... chronic kidney disease patients may be a strong indicator ... in the Journal of the American Society of ... Hopkins Bloomberg School of Public Health assert that coronary ... atherosclerosis in predicting the risk of heart disease among ... all patients with chronic kidney disease (CKD) die from ...
(Date:8/21/2014)... (PRWEB) August 21, 2014 Pulmonary ... with an Education Forum for PH patients and ... Who:    The Pulmonary Hypertension Association – the ... find ways to prevent and cure pulmonary hypertension ... affects the functioning of the heart and can ...
(Date:8/21/2014)... Researchers have pinpointed the environmental source of fungal infections ... for decades. It literally grows on trees. , The ... 13-year-old girl, who spent the summer gathering soil and ... by infections of the fungus named Cryptococcus gattii ... which encompasses a number of species including C. ...
(Date:8/21/2014)... -- Black mothers are less likely than white moms ... why: Hospitals in neighborhoods with many black residents do ... more white residents, a U.S. government study finds. ... in medical centers where the black population is higher ... Control and Prevention reported Thursday. These practices include ...
(Date:8/21/2014)... THURSDAY, Aug. 21, 2014 (HealthDay News) -- Among seniors, ... suggests. The study involved more than 2,500 people, aged ... the study and again two, six and eight years later. ... in the person,s risk of death during the study period, ... and effect, researchers led by Sharon Christ of Purdue University ...
Breaking Medicine News(10 mins):Health News:Measuring calcium buildup to predict heart disease in those with chronic kidney disease 2Health News:Pulmonary Hypertension Association Goes On the Road to Houston With an Education Forum for PH Patients and Families to Help Fight Rare Lung Disease 2Health News:Pulmonary Hypertension Association Goes On the Road to Houston With an Education Forum for PH Patients and Families to Help Fight Rare Lung Disease 3Health News:Fungus deadly to AIDS patients found to grow on trees 2Health News:Racial Disparities in Breast-Feeding May Start With Hospitals, Study Suggests 2Health News:Failing Vision Tied to Shorter Lifespans for Seniors 2
... Interim Results from National Chronic Disease ... ... participants in the Diabetes Ten City Challenge (DTCC) improved across,all ... of,the program, the American Pharmacists Association (APhA) Foundation,announced today., ...
... CHAPEL HILL, N.C., March 12 R&D structure ... is,essential to pharmaceutical companies. In a competitive market ... process increases -- the need to have an,optimized ... Discover the best-suited organizational structure that promotes rapid,growth, ...
... Millennium,Pharmaceuticals, Inc. (Nasdaq: MLNM ) ... Annual Lehman Brothers Global Healthcare Conference will ... visiting the Investors section of the,Company,s website, ... ), The presentation will include ...
... XTNT ) today announced that Gregory D. Casciaro, ... Company,s 28th Annual,Health Care Conference on Tuesday, March 18, ... at the Boston Marriot Copley Place in Boston, MA., ... device company focused on developing and,commercializing innovative customizable drug ...
... its ongoing effort to,give consumers information to improve ... four area hospitals have been,selected as Blue Distinction ... Distinction(R) is a nationwide program created to give ... and to work with their,health care providers to ...
... 12 Accuray,Incorporated (Nasdaq: ARAY ), a global ... company received the 2008 North American Medical,Devices Product of ... Sullivan, for its CyberKnife(R) Robotic Radiosurgery System., The ... is presented each,year to the company that has demonstrated ...
Cached Medicine News:Health News:Diabetes Ten City Challenge Collaborative Model Shows Improved Patient Health Across Key Clinical Indicators 2Health News:Diabetes Ten City Challenge Collaborative Model Shows Improved Patient Health Across Key Clinical Indicators 3Health News:Diabetes Ten City Challenge Collaborative Model Shows Improved Patient Health Across Key Clinical Indicators 4Health News:R&D Quality Excellence: Proven Tactics Optimize the R&D Quality Organizations of Pharmaceutical and Biotech Industries 2Health News:Eleventh Annual Lehman Brothers Global Healthcare Conference to Webcast Millennium Presentation 2Health News:Independence Blue Cross Announces Blue Distinction Centers for Complex and Rare Cancers(SM) in Philadelphia 2Health News:Independence Blue Cross Announces Blue Distinction Centers for Complex and Rare Cancers(SM) in Philadelphia 3Health News:Accuray's CyberKnife System Receives 2008 North American Medical Devices Product of the Year Award From Frost & Sullivan 2Health News:Accuray's CyberKnife System Receives 2008 North American Medical Devices Product of the Year Award From Frost & Sullivan 3
... Line ULTRA® Suctionaid® tracheostomy tubes provide an ... secretions from above the tracheostomy tube cuff. ... tracheostomy tubes provide an additional lumen to ... the tracheostomy tube cuff helping to reduce ...
Fenestrations allow your patients to vocalize when cuff is deflated...
The all silicone construction of the shaft and neck flange provides the utmost in patient comfort. , ,The Aire-Cuf® tracheostomy tube offers a more traditional and familiar air-filled cuff desig...
... Built-in 15 mm ISO termination for ... inner cannula in place. , ,Clearly ... inner cannula system , ,The Portex® ... constructed of siliconized polyvinyl chloride, providing a ...
Medicine Products: